Karen Rittweger

1.8k total citations · 1 hit paper
17 papers, 1.3k citations indexed

About

Karen Rittweger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Karen Rittweger has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Hepatology. Recurrent topics in Karen Rittweger's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (4 papers) and Colorectal Cancer Surgical Treatments (3 papers). Karen Rittweger is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (4 papers) and Colorectal Cancer Surgical Treatments (3 papers). Karen Rittweger collaborates with scholars based in United States, Australia and Switzerland. Karen Rittweger's co-authors include Josep Tabernero, Filippo de Braud, Hans‐Joachim Schmoll, Eric Van Cutsem, Jean A. Maroun, Daniel G. Haller, Mark Hill, Timothy Price, Frank Gilberg and Silke Hoersch and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Clinical Cancer Research.

In The Last Decade

Karen Rittweger

17 papers receiving 1.3k citations

Hit Papers

Capecitabine Plus Oxaliplatin Compared With Fluorouracil ... 2011 2026 2016 2021 2011 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
    2011 533 citations Daniel G. Haller, Josep Tabernero et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Rittweger United States 14 967 367 280 248 173 17 1.3k
Janja Ocvirk Slovenia 17 1.0k 1.1× 376 1.0× 231 0.8× 179 0.7× 226 1.3× 69 1.3k
H. Kröning Germany 13 1.0k 1.1× 592 1.6× 254 0.9× 199 0.8× 231 1.3× 26 1.5k
G. Pérez-Manga Spain 13 1.1k 1.2× 322 0.9× 282 1.0× 244 1.0× 157 0.9× 25 1.3k
G. Comella Italy 21 978 1.0× 435 1.2× 209 0.7× 146 0.6× 90 0.5× 70 1.2k
L. Leong United States 16 648 0.7× 241 0.7× 238 0.8× 144 0.6× 188 1.1× 41 1.0k
Keon Woo Park South Korea 14 707 0.7× 598 1.6× 387 1.4× 333 1.3× 73 0.4× 44 1.3k
Nikolaos Ziras Greece 17 996 1.0× 369 1.0× 207 0.7× 121 0.5× 181 1.0× 55 1.2k
Thierry Guillot France 11 872 0.9× 338 0.9× 275 1.0× 148 0.6× 178 1.0× 21 1.1k
Mitsukuni Suenaga Japan 21 1.1k 1.1× 533 1.5× 240 0.9× 205 0.8× 147 0.8× 149 1.5k
James D. Ahlgren United States 15 1.1k 1.2× 359 1.0× 343 1.2× 218 0.9× 101 0.6× 36 1.4k

Countries citing papers authored by Karen Rittweger

Since Specialization
Citations

This map shows the geographic impact of Karen Rittweger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Rittweger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Rittweger more than expected).

Fields of papers citing papers by Karen Rittweger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Rittweger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Rittweger. The network helps show where Karen Rittweger may publish in the future.

Co-authorship network of co-authors of Karen Rittweger

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Rittweger. A scholar is included among the top collaborators of Karen Rittweger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Rittweger. Karen Rittweger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Schmoll, Hans‐Joachim, Josep Tabernero, Jean A. Maroun, et al.. (2015). Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Journal of Clinical Oncology. 33(32). 3733–3740. 194 indexed citations
2.
3.
Spigel, David R., Martin J. Edelman, Tony Mok, et al.. (2012). The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). TPS7616–TPS7616. 13 indexed citations
4.
5.
Schmoll, Hans‐Joachim, Josep Tabernero, Jean A. Maroun, et al.. (2012). Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. Journal of Clinical Oncology. 30(4_suppl). 388–388. 16 indexed citations
6.
Haller, Daniel G., Josep Tabernero, Jean A. Maroun, et al.. (2011). Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. Journal of Clinical Oncology. 29(11). 1465–1471. 533 indexed citations breakdown →
7.
Buzdar, Aman U., Binghe Xu, Raghunadharao Digumarti, et al.. (2011). Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Annals of Oncology. 23(3). 589–597. 11 indexed citations
8.
Zhi, Jianguo, Eric X. Chen, Pierre Major, et al.. (2011). A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 68(5). 1199–1206. 14 indexed citations
9.
Cassidy, J, Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2011). XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British Journal of Cancer. 105(1). 58–64. 178 indexed citations
10.
Haller, Daniel G., Josep Tabernero, Jean A. Maroun, et al.. (2009). 5LBA First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). European Journal of Cancer Supplements. 7(3). 4–4. 22 indexed citations
11.
Brennan, Barbara J., Lillian L. Siu, C. Cripps, et al.. (2007). Pharmacokinetic (PK) interactions between capecitabine (X), oxaliplatin (O) and bevacizumab (A) when used in combination for first-line treatment of metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 25(18_suppl). 2554–2554. 5 indexed citations
12.
Talpaz, Moshe, Ashok Rakhit, Karen Rittweger, et al.. (2005). Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia. Clinical Cancer Research. 11(17). 6247–6255. 26 indexed citations
13.
Motzer, Robert J., Ashok Rakhit, John F. Thompson, et al.. (2002). Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma. Annals of Oncology. 13(11). 1799–1805. 38 indexed citations
14.
Motzer, Robert J., Ashok Rakhit, Michelle S. Ginsberg, et al.. (2001). Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 19(5). 1312–1319. 73 indexed citations
15.
Zeuzem, Stefan, U. Hopf, Vicente Carréño, et al.. (1999). A Phase I/Ii Study of Recombinant Human Interleukin–12 in Patients With Chronic Hepatitis C. Hepatology. 29(4). 1280–1287. 41 indexed citations
16.
Eron, Lawrence J., et al.. (1993). Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon.. Sexually Transmitted Infections. 69(2). 91–93. 26 indexed citations
17.
Fürst, Daniel E., et al.. (1988). Serum concentration and dose-response relationships for carprofen in rheumatoid arthritis. Clinical Pharmacology & Therapeutics. 44(2). 186–194. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janja Ocvirk Breakdown of academic impact, for papers by H. Kröning Breakdown of academic impact, for papers by G. Pérez-Manga Breakdown of academic impact, for papers by G. Comella Breakdown of academic impact, for papers by L. Leong Breakdown of academic impact, for papers by Keon Woo Park Breakdown of academic impact, for papers by Nikolaos Ziras Breakdown of academic impact, for papers by Thierry Guillot Breakdown of academic impact, for papers by Mitsukuni Suenaga Breakdown of academic impact, for papers by James D. Ahlgren
Rankless by CCL
2026